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Abstract 
Objective To assess antibiotic availability and use in health facilities in low- and 
middle-income countries, using the service provision assessment and service 
availability and readiness assessment surveys. 
Methods We obtained data on antibiotic availability at 13 561 health facilities 
in 13 service provision assessment and 8 service availability and readiness 
assessment surveys. In 10 service provision assessment surveys, child consultations 
with health-care providers were observed, giving data on antibiotic use in 22 699 
children. Antibiotics were classified as access, watch or reserve, according to the 
World Health Organization’s AWaRe categories. The percentage of health-care 
facilities across countries with specific antibiotics available and the proportion of 
children receiving antibiotics for key clinical syndromes were estimated. 
Findings The surveys assessed the availability of 27 antibiotics (19 access, 7 
watch, 1 unclassified). Co-trimoxazole and metronidazole were most widely available, 
being in stock at 89.5% (interquartile range, IQR: 11.6%) and 87.1% (IQR: 15.9%) of 
health facilities, respectively. In contrast, 17 other access and watch antibiotics were 
stocked, by fewer than a median of 50% of facilities. Of the 22 699 children observed, 
60.1% (13 638) were prescribed antibiotics (maostly co-trimoxazole or amoxicillin). 
Children with respiratory conditions were most often prescribed antibiotics (76.1%; 
8972/11 796) followed by undifferentiated fever (50.1%; 760/1518), diarrhoea (45.7%; 
1293/2832) and malaria (30.3%; 352/1160). 
Conclusion Routine health facility surveys provided a valuable data source on 
the availability and use of antibiotics in low- and middle-income countries. Many 
access antibiotics were unavailable in a majority of most health-care facilities. 
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Introduction 
The reliable availability of affordable, high-quality antibiotics remains a major global 
concern.1,2 Antibiotics are vital for preventing and treating bacterial infection, without which 
the risk of surgery becomes greater, managing noncommunicable disease becomes more 
difficult and universal health coverage becomes less attainable. Sustainable development goal 
(SDG) 3.8 includes the achievement of, “access to safe, effective, quality and affordable 
essential medicines and vaccines for all.”3 However, although ensuring universal access to 
antimicrobials can save millions of lives,4 excessive and inappropriate use must be limited to 
avoid the development of antimicrobial resistance. 
An insight into the specific types of antibiotics available and used in different 
countries is vital. When the correct medication is not available, it may be substituted by an 
alternative, such as a broad-spectrum antibiotic, and patients may buy over-the-counter 
medicines that could be falsified or of a poor quality. These alternatives can be less effective, 
have more adverse effects and could drive the development of antimicrobial resistance.5,6 The 
reduced effectiveness of antimicrobials and the increasing burden of antimicrobial resistance 
are particularly problematic in low- and middle-income countries where multidrug-resistant 
pathogens (e.g. Escherichia coli and Salmonella species) are common.6–9 
Although it may be unrealistic and undesirable to achieve universal access to all 
antibiotics at all health facilities, it should be possible to ensure consistent access to key 
antibiotics. The AWaRe (access, watch, reserve) antibiotics categories (Box 1 and Table 1; 
available at: http://www.who.int/bulletin/volumes/98/##/##-######) of the World Health 
Organization’s (WHO’s) 2019 list of essential medicines includes a core set of antibiotics 
that should be available everywhere (i.e. access antibiotics) because they are the first and 
second choice for treating common or severe clinical syndromes.10,12 These antibiotics are 
generally narrow-spectrum agents with a low risk of resistance selection and of adverse 
effects. The other two AWaRe categories are: (i) watch antibiotics, which have a higher risk 
of toxicity or resistance development; and (ii) reserve antibiotics, which should be used as a 
last resort in specific clinical situations and whose effectiveness should be preserved.10,12 
Monitoring the progress of efforts to address antimicrobial resistance requires data on 
not only resistance patterns but also on the availability and use of antibiotics and how they 
are changing. External surveys of health facilities carried out as part of service provision 
assessments and service availability and readiness assessments include data on antibiotic 
availability and potentially provide countries with an overview of the antibiotics available 
locally (Box 2; http://www.who.int/bulletin/volumes/98/##/##-######).13,14 Other 
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approaches to monitoring the availability of drugs (including antibiotics) are the medicines 
monitoring tools used to generate data for monitoring SDGs (currently used in five countries 
and being extended to others).15 Several countries also track stock-outs of medicines (usually 
including some antibiotics) at individual facilities as a performance metric for health systems. 
The aim of this study was to determine whether external assessments of health 
facilities in low- and middle-income countries can provide data on antibiotic availability and 
use in general and on the availability of key antibiotics in particular. To do this, we used data 
from service provision assessment and service availability and readiness assessment surveys 
in low- and middle-income countries to calculate the proportion of health facilities that held 
stocks of core antibiotics in each country and the proportion of children prescribed antibiotics 
for key clinical syndromes. 
Methods 
The service provision assessment includes a cross-sectional, health facility survey developed 
by ICF International Inc. under the Demographic and Health Surveys (DHS) programme 
funded by the United States Agency for International Development.13 The service availability 
and readiness assessment surveys are conducted by WHO using very similar methods (Box 2 
and Table 2).16 Full details of the surveys’ procedures, methods and questionnaires are 
available online.17,18 For both types of survey, health facilities were selected in each country 
from national facility lists, which included private, non-profit and faith-based hospitals and 
health centres.19 The surveys used nationally representative samples of the formal health 
system in all countries except Haiti, Malawi, Mauritania, Namibia, Rwanda and Uganda, 
where all or almost all facilities were included. 
Each assessment was based on an inventory questionnaire completed by trained 
interviewers from WHO or the DHS programme during a visit to the health facility and 
provided an external validation of the facility’s functioning.20 Antibiotics were audited to 
determine if they were in stock at each facility on the interview day. In most service 
provision assessment surveys, interviewers also observed child consultations to assess 
adherence to standards of care provision and antibiotic prescription. 
Details of the survey design are available online for most countries.13,21 In addition, 
data sets for the service provision assessments are publicly available from the DHS 
programme and service availability and readiness assessment data sets are available from 
WHO. The surveys included in our study sample were those: (i) for which microdata were 
available (rather than just survey reports); (ii) that had been conducted after 2000 (studies 
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completed between 1997 and 2000 were less comparable because different survey 
instruments were used); and (iii) that provided the most recent data set available for the 
country (available in the data repository).22 For countries where several surveys had been 
performed, we used the latest survey that provided data on antibiotic use. 
Antibiotic availability and use 
An antibiotic was considered available at a facility if the medications in stock on the 
assessment day were within their usage dates and were, therefore, available for patients, as 
stipulated in WHO methods for measuring medicine availability.23 Oral and intravenous 
formulations were assessed separately. Each survey questionnaire was country-specific and 
the number of antibiotics assessed varied slightly between countries. If the availability of a 
particular antibiotic was not assessed in a country, data for that antibiotic were classed as 
missing data. The availability of an antibiotic in a country was defined as the percentage of 
health facilities in that country where the antibiotic was available. The median and 
interquartile range (IQR) of the percentage availability across all countries were calculated. 
Availability is presented according to AWaRe categories (Table 1). 
The use of antibiotics for treating particular illnesses in children was assessed in 
service provision assessment surveys that included observations of child consultations. 
Trained interviewers asked health-care providers (e.g. a medical doctor, nurse, nonphysician 
clinical specialist or midwife) about the children’s diagnoses and what treatment was 
prescribed or provided. Diagnoses were based on the children’s medical history and physical 
examinations, except for malaria, where the diagnosis was based on a rapid diagnostic test, 
blood smear microscopy or clinical findings, depending on the services available – details are 
provided in the online observation protocol.24 
The percentage of children who were prescribed, or provided with, an antibiotic for 
each condition diagnosed was calculated for each survey country individually and overall. 
The diagnostic categories were: (i) pneumonia; (ii) asthma; (iii) other respiratory tract 
infection, including other upper respiratory infections and unknown respiratory illness; 
(iv) ear infection; (v) throat infection; (vi) diarrhoea; (vii) malaria; (vii) undifferentiated fever 
or measles; and (viii) any other illness. If a child was diagnosed with more than one 
condition, they were regarded as being diagnosed with the condition for which they were 
most likely to receive an antibiotic – this was determined using WHO’s 2017 model list of 
essential medicines for children.25  
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The association between the availability and use of each antibiotic was assessed by 
multivariable logistic regression, which included adjustment for confounding variables such 
as the child’s sex and age, the survey country and year, the type of facility, the condition 
diagnosed, the facility’s managing authority, the role of the health-care provider and season. 
Our study abided by WHO ethics and research committee rules and procedures on research 
involving human participants. 
Results 
We identified 65 (38 service availability and readiness assessment and 27 service provision 
assessment) surveys conducted between 1997 and 2017. Although other surveys may have 
been carried out, we were not able to obtain either data or reports for our analysis. Of the 65, 
we excluded 3 because they were conducted between 1997 and 2000, 19 because more recent 
data were available for the country surveyed and 22 because no microdata were available 
(available in the data repository).22 The final sample included surveys from 20 countries and 
one territory (13 service provision assessment surveys and 8 service availability and 
readiness assessment surveys) conducted between 2004 and 2017, mainly in Africa. They 
covered a total of 13 561 health facilities (Table 3), of which 9111 (67.2%) were government 
facilities. The most common type of facility was the health centre, which comprised 39.1% 
(5302) of facilities. Overall, the surveys investigated the availability of 27 antibiotic 
formulations (19 access, 7 watch and 1 unclassified antibiotic); 17 were oral and 10 were 
intravenous. Ten of the service provision assessment surveys collected data on antibiotic use 
in a total of 22 699 children (Table 4): 99.4 % (21 604/21 715) of children whose ages were 
known were younger than 5 years. 
Antibiotic availability 
The median availability of all antibiotics at all health facilities in the surveys was 48.9%. The 
access antibiotics were most often investigated in surveys and were the most widely available 
at health facilities. Although no access antibiotic was universally available, the median 
proportion of facilities across countries with co-trimoxazole, metronidazole and amoxicillin 
available was 89.5% (IQR: 12.6%), 87.1% (IQR: 15.9%) and 83.8% (IQR: 26.4%), 
respectively (Fig. 1). Some access antibiotics (i.e. ampicillin, cloxacillin, amoxicillin with 
clavulanate, tetracycline, cefalexin and clindamycin) were available in a median of 30.9% or 
fewer health facilities, although cefalexin and clindamycin were assessed in only six and five 
surveys, respectively (Table 5 and data repository).22 
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The surveys assessed seven watch antibiotics, which were less frequently available 
than access antibiotics. The most widely available watch antibiotic was erythromycin, which 
had a median overall availability of 65% (IQR: 34; Fig. 1, Table 5, data repository).22 Across 
all AWaRe categories, there were some large variations between and within countries; for 
example, the proportion of facilities with benzathine benzylpenicillin (an access antibiotic) in 
stock ranged from 4% in Sierra Leone to 96% in Benin (Table 5). In total, 17 access and 
watch antibiotics were, on average, stocked by fewer than 50% of facilities. 
Antibiotic use 
Overall, 60.1% (13 638/22 699) of children whose consultations were observed were 
prescribed an antibiotic (Table 4); of the 13 638, 4724 (34.6%) received co-trimoxazole, 4525 
(33.2%) received amoxicillin and 416 (3.1%) received intravenous benzylpenicillin (all 
access antibiotics). Children diagnosed with a respiratory condition were most likely to be 
prescribed an antibiotic – the proportion was 76.1% (8972/11 796). Specifically, 88.9% 
(1998/2248), 80.9% (722/892) and 72.2% (5701/7894) of children with pneumonia, throat 
infections and other respiratory tract infections, respectively, received an antibiotic (Table 6). 
In addition, an antibiotic was prescribed for 50.1% (760/1518) of undifferentiated fever 
cases, 45.7% (1293/2832) of diarrhoea cases and 30.3% (352/1160) of malaria cases. 
Amoxicillin and co-trimoxazole were the most commonly prescribed antibiotics for all 
diagnoses, except throat infection (Fig. 2). Multivariable logistic regression showed that the 
availability of an antibiotic was significantly associated with its use: the odds that amoxicillin 
would be used if it were available was 1.40 (95% confidence interval, CI: 1.26–1.55). The 
corresponding odds was 1.38 (95% CI: 1.12–1.71) for benzylpenicillin, 1.94 (95% CI: 1.63–
2.29) for co-trimoxazole, 1.24 (95% CI: 0.98–1.56) for all other intravenous antibiotics and 
1.02 (95% CI: 0.88–1.18) for all other oral antibiotics. 
Discussion 
Using the data from service provision assessment and service availability and readiness 
assessment surveys have great potential for informing countries about the pattern of antibiotic 
use at health facilities. In addition, the data can also be used by antimicrobial resistance 
coordination committees. As the majority of facilities surveyed in our study were health 
centres, clinics or dispensaries, it is appropriate that access antibiotics were more widely 
available than watch antibiotics. Of access antibiotics, several were available at most 
facilities, such as amoxicillin and co-trimoxazole. However, other access antibiotics were 
much less available: gentamycin, which is used for treating neonatal sepsis and other severe 
infections,26 was available at only 56.6% of facilities. Moreover, most facilities had shortages 
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of watch antibiotics, which have a key therapeutic role in some infections. Although the 
quantity required may be small, they should be available at all health facilities. 
Overall, we found that 60.1% of children whose consultations were observed were 
prescribed an antibiotic. Although there may be valid reasons for treating conditions such as 
lower respiratory tract infection and diarrhoea, the high percentage of prescribing suggests 
antibiotics were being used inappropriately, as has been observed both anecdotally and in 
other studies.27–29 Among diagnoses, respiratory conditions had the highest percentage of 
antibiotic prescription. However, many children were prescribed antibiotics for conditions for 
which they are not usually indicated, including undifferentiated fever, diarrhoea and malaria. 
Globally there is considerable debate about the importance of access to antibiotics, 
but this frequently focuses on national supplies. Some studies have used pharmaceutical sales 
data, which reflect the antibiotic consumption of whole countries rather than individuals or 
communities.5,30,31 Nevertheless, despite the different data sources used, the proportion of 
prescribed antibiotics that were access antibiotics was broadly similar across paediatric 
studies. One international study found that 76.0% of all antibiotics used were access 
antibiotics (compared with 72.4% in our study) and 30.7% were amoxicillin (compared with 
33.9% in our study).30 However, there are inconsistencies between health facility surveys and 
pharmaceutical sales studies because the antibiotics with the highest sales are not always 
available at health facilities. For example, in our study, amoxicillin with clavulanic acid was 
available at only 17.4% of health facilities, whereas recent global pharmaceutical sales data 
indicate it is used in almost equal amounts to amoxicillin, which was available at 83.8% of 
facilities in our study.31 Similarly, cefixime is also one of the most commonly used 
antibiotics according to pharmaceutical sales but was available at only 12.9% of facilities.31 
These discrepancies suggest there may be a divergence between supply and use in some 
countries. There might be differences in prescribing patterns between health facilities and 
other vendors who were not covered in our study but whose antibiotic sales were reflected in 
pharmaceutical data. 
The lack of high-quality data at the community level presents a barrier to 
understanding antibiotic access and use. One systematic analysis of antibiotic consumption in 
Africa found that studies were frequently limited by their small sample size, a lack of 
adherence to WHO recommendations on reporting medicines and poor reporting of study 
details,32 which illustrates the difficulty of obtaining meaningful data in low- and middle-
income countries. Despite methodological difficulties, community studies in India, Nepal, 
Viet Nam and sub-Saharan Africa have reported high percentages (and possibly 
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inappropriate) of antibiotic prescription in the range of 41.0–85.0%, similar to our finding in 
children.33–39 The main advantage of these analyses is that they can identify the diseases for 
which antibiotics are most commonly used – they consistently showed the majority of 
antibiotic prescriptions were for respiratory conditions.33,34,36,37,40,41 They also documented 
high antibiotic use by individuals with malaria, despite rapid malaria diagnostic tests being 
available. The antibiotic prescription rates for diarrhoea and undifferentiated fever reported 
across Africa and Asia were comparable with our findings.34,39,42–46 
In our study, amoxicillin accounted for 33.9% of antibiotics prescribed to children, 
which was low relative to other community studies where amoxicillin made up over half of 
prescriptions.34,40,47,48 We found the variation in availability between countries was greater 
for amoxicillin than co-trimoxazole, which is often widely distributed within countries 
because HIV programmes have made substantial investments in supply chain management to 
ensure its availability for prophylaxis.49,50 However, the ready availability of co-trimoxazole 
can result in it being heavily prescribed even when inappropriate.37,47 As expected, 
availability was correlated with use, though the association was weak, probably because 
patients were instructed to buy specific medicines elsewhere if they were not available at a 
facility. 
One strength of our study is that the surveys were reliably conducted in many 
countries, had large sample sizes and adopted a standard approach.20 Both assessment 
surveys are well suited to assessing all aspects of health-care provision and the physical and 
human resources required. Although their total cost is high, these surveys offer a more 
efficient and cost–effective way of obtaining basic information on antibiotic consumption 
than specific surveys. Moreover, they can help monitor the actions taken to manage 
antimicrobial resistance both nationally and globally. 
There are some limitations, however. First, our study was primarily an exploratory 
analysis of the usefulness of health facility surveys in low- and middle-income countries. 
Second, the survey data did not cover drug sources such as local pharmacies or informal 
providers and not all antibiotics were included (e.g. no reserve antibiotics were monitored). 
Third, the availability of a medication may not correlate with its use because: (i) some 
countries use drug availability as a performance indicator, which may encourage suppliers to 
keep key medicines in stock instead of dispensing them; and (ii) the cost of an antibiotic 
(which was not recorded in surveys) may have been high enough to prevent individuals 
accessing it. Fourth, surveys were cross-sectional and thus reflected the status of facilities on 
one specific day, which may limit the generalizability of a survey’s findings beyond the 
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specific country and year in which it was conducted. In particular, as some surveys were 
conducted over 10 years ago (i.e. in Egypt, Guyana and Uganda), recent antibiotic 
availability may have been underestimated. Finally, health workers are more likely to 
prescribe in accordance with guidelines when being observed. 
More surveys are planned and underway. Future surveys will also collect information 
on the price of essential medicines to patients. Although assessments of facilities may not be 
able to provide detailed information on the formulation of drugs or on prescribing behaviour, 
they will continue to give insights into antibiotic availability and use in primary and 
secondary care, where monitoring capacity is limited but antibiotic use is greatest. Future 
surveys would benefit from the inclusion of standard questions on antibiotics based on 
AWaRe categories. As data from more surveys become available, future research will be able 
to monitor changing patterns of use. 
This study of service provision assessment and service availability and readiness 
assessment surveys of health facilities in low- and middle-income countries demonstrated 
that more data on antibiotic availability and use are available than previously reported. These 
data can help countries evaluate the risk of antimicrobial resistance. Both surveys provide an 
important and expanding resource that can be used to improve understanding of local and 
global antibiotic consumption patterns, without the need for collecting new data. Our study 
found that first-line access antibiotics were unavailable at many health facilities in some 
countries – investment in antibiotic supply chain management is therefore needed. We also 
found that antibiotics were used extensively in primary care, often for conditions for which 
they are not usually indicated. 
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Box 1. AWaRe antibiotics categories 
In 2017, the World Health Organization’s Expert Committee on the Selection and Use 
of Essential Medicines undertook a comprehensive review of antibacterials on the 
Model List of Essential Medicines that are used to treat common, priority infectious 
syndromes.10,11 The antibiotics included on the list were revised and listed as first- or 
second-choice treatments for specific indications. The Committee also proposed 
assigning antibiotics to three groups: access, watch and reserve antibiotics (i.e. the 
AWaRe categories). 
• Access antibiotics are first- and second-choice antibiotics for the empirical treatment 
of most common infectious syndromes;  
• Watch antibiotics include classes of antibiotics that have a higher potential for the 
development of resistance and whose use as first- or second-choice treatment should 
be limited to a small number of syndromes or patient groups; and 
• Reserve antibiotics are antibiotics that should be used mainly as treatments of last 
resort. 
The AWaRe categories consider the need to ensure access to necessary antibiotics, 
the need for effective antimicrobial stewardship and the impact of different antibiotics 
on antimicrobial resistance. They provide a useful tool for identifying which antibiotics 
to monitor and for informing procurement and supply policies. 
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Box 2. Service availability and readiness assessment surveys and service 
provision assessment surveys 
Service availability and readiness assessment surveys and service provision 
assessment surveys are health facility surveys that assess the availability and 
readiness of different health services in a country with reference to accepted standards 
of care. In addition, service provision assessment surveys also include observations 
of patient care and evaluate client satisfaction with service delivery. Both survey tools 
generate indicators of service availability and readiness that provide reliable and 
regular information on: (i) service delivery processes and provisions, such as the 
availability of key human and infrastructure resources, basic equipment, basic 
amenities, essential medicines and diagnostic capacities; and (ii) the readiness of 
facilities to provide basic health-care interventions, such as family planning, child 
health services, basic and comprehensive emergency obstetric care, and the 
treatment of HIV infection, tuberculosis, malaria and noncommunicable diseases. 
Currently, service availability and readiness assessment surveys are being 
implemented in 32 countries and service provision assessment surveys are being 
implemented in 17. As the average time between surveys is 2 to 3 years, they are not 
intended to replace routine supervision and monitoring. Instead, they collect 
information that can provide an external validation of whether health systems are 
functioning as reported. In particular, they provide an ideal way of verifying service 
standards in countries where accreditation and certification systems are undergoing 
revision and improvement. 
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Table 1. The AWaRe (access, watch, reserve) antibiotics categories of the 
World Health Organization’s 2019 list of essential medicines10 
Antibiotics categorya 
Access Watch Reserve Otherb 
Antibiotics assessed in the surveysc 
Amoxicillin 
Ampicillin 
Amoxicillin with clavulanic acid 
Benzathine benzylpenicillin 
Cloxacillin 
Chloramphenicol 
Clindamycin 
Doxycycline 
Gentamycin 
Metronidazole 
Procaine benzylpenicillin 
Streptomycin 
Sulfamethoxazole and 
trimethoprim (co-trimoxazole) 
Tetracycline 
Cefalexin 
Penicillin 
Ciprofloxacin 
Third-generation cephalosporins, with or 
without a β-lactamase inhibitor (i.e. cefixime, 
ceftriaxone and cefotaxime) 
Macrolides (i.e. azithromycin, clarithromycin 
and erythromycin) 
None Kanamycin 
Antibiotics not assessed in the surveysc 
Nitrofurantoin 
Phenoxymethylpenicillin 
Spectinomycin 
First-generation cephalosporins 
other than cefalexin 
Quinolones and fluoroquinolones other than 
ciprofloxacin (e.g. levofloxacin, moxifloxacin 
and norfloxacin) 
Third-generation cephalosporins, with or 
without a β-lactamase inhibitor, other than 
cefixime, ceftriaxone and cefotaxime (e.g. 
ceftazidime) 
Glycopeptides (e.g. teicoplanin and 
vancomycin) 
Antipseudomonal penicillins with a β-
lactamase inhibitor (e.g. piperacillin with 
tazobactam) 
Carbapenems (e.g. meropenem and 
imipenem with cilastatin) 
Penems (e.g. faropenem) 
Second-generation cephalosporins 
Aztreonam 
Fourth-generation 
cephalosporins (e.g. 
cefepime) 
Fifth-generation 
cephalosporins (e.g. 
ceftaroline) 
Polymyxins (e.g. 
polymyxin B and 
colistin) 
Fosfomycin 
(intravenous) 
Oxazolidinones (e.g. 
linezolid) 
Daptomycin 
None 
a Access antibiotics are the first and second choice for treating common or severe clinical syndromes, 
watch antibiotics have a higher risk of toxicity or resistance development and reserve antibiotics 
should be used as a last resort to preserve their effectiveness (Box 1). 
b This column lists only the one unclassified antibiotic that was included in surveys. 
c Surveys include the service availability and readiness assessments and service provision 
assessments. 
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Table 2. Comparison of service provision assessment and service availability 
and readiness assessment surveys 
Characteristic Survey 
Service provision assessment13 Service availability and readiness 
assessment16 
Survey conducted by DHS using the USAID–WHO inventory questionnaire WHO and USAID 
Background The survey was developed by updating the method used 
in service availability and readiness assessment surveys 
to cover more areas and to give a more comprehensive 
overview. The topics covered include equipment, 
amenities, essential medicines, diagnostic capacity and 
the readiness of health facilities to provide basic health-
care interventions for family planning, child health, 
obstetric care, HIV infection, tuberculosis, malaria and 
noncommunicable diseases 
The survey was developed through a joint 
WHO–USAID collaboration. The health 
facility assessment tool was designed to 
assess and monitor service availability and 
the readiness of a country’s health sector, 
and to generate evidence to support planning 
and management. The topics covered include 
equipment, amenities, essential medicines, 
diagnostic capacity and the readiness of 
health facilities to provide basic health-care 
interventions for family planning, child health, 
obstetric care, HIV infection, tuberculosis, 
malaria and noncommunicable diseases 
Survey elements (i) Inventory questionnaire (including data on antibiotic 
availability); (ii) observation protocols and interviews with 
clients leaving facilities about antenatal care, family 
planning and sick children (including data on antibiotic use 
in children); and (iii) Service provision assessment health 
worker and health-care provider interview questionnaire 
Inventory questionnaire (including data on 
antibiotic availability) 
Method and health 
facilities included 
(i) The survey typically includes 400–700 facilities (surveys 
can be carried out either as a census or as a 
representative sample of health facilities) selected from 
the country’s master facility list; (ii) surveys are typically 
conducted by 10–15 teams, each comprising 3–4 
interviewers (mostly health workers); and (iii) interviewers 
collect data from the people in charge or the most 
knowledgeable people at each facility using the inventory 
questionnaire, observe consultations and interview clients 
leaving facilities 
These surveys use the same method as 
service provision assessment surveys, except 
that consultations are not observed and 
clients are not interviewed on leaving facilities 
Data availability Available online for each country WHO has all data 
DHS: Demographic and Health Surveys; HIV: human immunodeficiency virus; USAID: United States 
Agency for International Development; WHO: World Health Organization. 
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Table 3. Health facilities, service provision assessment and service availability and readiness assessment surveys in low- and 
middle-income countries, 2004–2017 
Country or 
territory 
Survey type (year) No. of facilities 
surveyed (% of all 
facilities in 
country or 
territory)a 
 No. of facilities (% of facilities surveyed)b 
Type of facility  Managing authority 
Hospital Health centre Clinic or 
dispensary 
Government Private Not-for-profit 
organization 
Bangladesh SPA (2014) 1 596 (8.3)  185 (11.6) 541 (33.9) 870 (54.5)  1352 (84.7) 103 (6.5) 141 (8.8) 
Benin SARA (2014) 788 (55.0)  46 (5.8) 596 (75.6) 146 (18.5)  591 (75.0) 60 (7.6) 137 (17.4) 
Democratic 
Republic of the 
Congo 
SARA (2013) 1 555 (9.6)  485 (31.2) 706 (45.4) 364 (23.4)  872 (56.1) 248 (15.9) 433 (27.8) 
Egyptc SPA (2004) 659 (12.9)  81 (12.3) 373 (56.6) 205 (31.1)  559 (84.8) 0 (0.0) 100 (15.2) 
Guyana SPA (2004) 155 (47.5)  30 (19.4) 69 (44.5) 56 (36.1)  30 (19.4) 69 (44.5) 47 (30.3) 
Haitic SPA (2013) 907 (100.0)  121 (13.3) 427 (47.1) 359 (39.6)  344 (37.9) 214 (23.6) 349 (38.5) 
Kenyac SPA (2010) 695 (11.2)  252 (36.3) 101 (14.5) 342 (49.2)  347 (49.9) 217 (31.2) 131 (18.8) 
Malawic SPA (2013–2014) 1 060 (100.0)  119 (11.2) 484 (45.7) 457 (43.1)  509 (48.0) 252 (23.8) 229 (21.6) 
Mauritania SARA (2013) 232 (100.0)  37 (15.9) 123 (53.0) 72 (31.0)  163 (70.3) 61 (26.3) 8 (3.4) 
Namibiac SPA (2009) 411 (92.2)  45 (10.9) 47 (11.4) 319 (77.6)  306 (74.5) 49 (11.9) 42 (10.2) 
Nepalc SPA (2015) 992 (21.0)  270 (27.2) 247 (24.9) 475 (47.9)  775 (78.1) 139 (14.0) 78 (7.9) 
Rwandac SPA (2017) 538 (96.9)  42 (7.8) 389 (72.3) 107 (19.9)  309 (57.4) 229 (42.6) 0 (0.0) 
Senegalc SPA (2017) 794 (21.1)  37 (4.7) 75 (9.4) 682 (85.9)  706 (88.9) 0 (0.0) 88 (11.1) 
Sierra Leone SARA (2016) 455 (36.0)  264 (58.0) 191 (42.0) 0 (0.0)  399 (87.7) 22 (4.8) 34 (7.5) 
Somalia SARA (2012) 149 (13.9)  11 (7.4) 73 (49.0) 65 (43.6)  144 (96.6) 0 (0.0) 3 (2.0) 
Togo SARA (2013) 100 (12.8)  32 (32.0) 39 (39.0) 29 (29.0)  75 (75.0) 9 (9.0) 13 (13.0) 
Ugandac SPA (2005) 491 (100.0)  119 (24.2) 372 (75.8) 0 (0.0)  351 (71.5) 140 (28.5) 0 (0.0) 
United Republic 
of Tanzaniac 
SPA (2014–2015) 1 200 (17.7)  263 (21.9) 380 (31.7) 557 (46.4)  783 (65.2) 188 (15.7) 204 (17.0) 
Zambia SPA (2015) 424 (23.0)  101 (23.8) 0 (0.0) 52 (12.3)  305 (71.9) 0 (0.0) 119 (28.1) 
Zanzibar SARA (2012) 79 (29.9)  8 (10.1) 69 (87.3) 2 (2.5)  77 (97.5) 1 (1.3) 1 (1.3) 
Zimbabwe SARA (2015) 275 (25.2)  62 (22.6) 0 (0.0) 184 (66.9)  114 (41.5) 18 (6.5) 46 (16.7) 
Total 13 SPAs, 8 SARAs 13 561 (18.3)  2610 (19.3) 5302 (39.1) 5343 (39.4)  9111 (67.2) 2019 (14.9) 2203 (16.2) 
SARA: Service Availability and Readiness Assessment; SPA: Service Provision Assessment. 
a The total number of facilities in each country or territory was based on the master facility list provided by health ministries. 
b Data on facility type and managing authority were not available for 306 and 222 facilities, respectively. Consequently, for some countries percentages do not total 
100%. 
c Child consultations were observed in this survey. 
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Table 4. Child consultations observed, service provision assessment surveys in low- and middle-income countries, 2004–2017 
Variable No. (%)a 
Country, year of survey  Total 
(n = 22 699) Egypt, 2004 
(n = 2069) 
Haiti, 2013 
(n = 2 450) 
Kenya, 2010 
(n = 2047) 
Malawi, 2013–
2014 (n = 3 438) 
Namibia, 2009 
(n = 1 578) 
Nepal, 2015 
(n = 2 229) 
Rwanda, 2017 
(n = 1 756) 
Senegal, 2017 
(n = 1 064) 
Uganda, 2005 
(n = 1 112) 
United Republic of 
Tanzania, 2014–
2015 (n = 4 956) 
 
Child’s age in 
years, mean (SD) 
1.8 (1.3) 1.7 (1.3) 1.9 (1.4) 1.8 (1.3) 1.9 (1.4) 1.9 (1.3) 1.8 (1.4) 1.6 (1.2) 1.6 (1.2) 1.7 (1.3)  1.8 (1.3) 
Male children 1164 (56.3) 1180 (48.2) 1080 (52.8) 1719 (50.0) 830 (52.6) 1266 (56.8) 927 (52.8) 558 (52.4) 553 (49.8) 2562 (51.7)  11 839 (52.2) 
Male physicians 1404 (67.9) 926 (37.8) 1109 (54.2) 2496 (72.6) 412 (26.1) 1738 (78.0) 904 (51.5) 497 (46.7) 647 (58.2) 3061 (61.8)  13 194 (58.1) 
Physician typeb             
Medical doctor 2069 (100) 1512 (61.7) 1197 (58.5) 55 (1.6) 61 (3.9) 341 (15.3) 120 (6.9) 105 (9.9) 5 (0.5) 344 (6.9)  5 809 (25.6) 
Nurse or midwife 0 (0.0) 936 (38.2) 792 (38.7) 591 (17.2) 1508 (95.6) 183 (8.2) 1614 (92.3) 899 (84.5) 381 (34.4) 1130 (22.8)  8 034 (35.4) 
Health-care 
assistantc 
0 (0.0) 0 (0.0) 0 (0.0) 2787 (81.1) 9 (0.6) 1705 (76.5) 3 (0.2) 0 (0.0) 718 (64.9) 3477 (70.2)  8 699 (38.3) 
Condition 
diagnosed 
            
Pneumonia 103 (5.0) 60 (2.4) 312 (15.2) 404 (11.8) 145 (9.2) 177 (7.9) 133 (7.6) 110 (10.3) 148 (13.3) 656 (13.2)  2 248 (9.9) 
Ear infection 46 (2.2) 70 (2.9) 53 (2.6) 74 (2.2) 46 (2.9) 108 (4.8) 50 (2.8) 12 (1.1) 29 (2.6) 64 (1.3)  552 (2.4) 
Throat infection 550 (26.6) 25 (1.0) 33 (1.6) 18 (0.5) 55 (3.5) 25 (1.1) 83 (4.7) 10 (0.9) 4 (0.4) 89 (1.8)  892 (3.9) 
Asthma 0 (0.0) 46 (1.9) 42 (2.1) 23 (0.7) 11 (0.7) 9 (0.4) 6 (0.3) 17 (1.6) 24 (2.2) 32 (0.6)  210 (0.9) 
Other respiratory 
tract infection 
649 (31.4) 605 (24.7) 959 (46.8) 1222 (35.5) 769 (48.7) 456 (20.5) 888 (50.6) 331 (31.1) 525 (47.2) 1490 (30.1)  7 894 (34.8) 
Malaria 0 (0.0) 106 (4.3) 298 (14.6) 184 (5.4) 18 (1.1) 5 (0.2) 39 (2.2) 12 (1.1) 135 (12.1) 363 (7.3)  1 160 (5.1) 
Diarrhoea 489 (23.6) 387 (15.8) 170 (8.3) 262 (7.6) 185 (11.7) 245 (11.0) 231 (13.2) 132 (12.4) 97 (8.7) 634 (12.8)  2 832 (12.5) 
Undifferentiated 
fever 
59 (2.9) 131 (5.3) 47 (2.3) 38 (1.1) 41 (2.6) 355 (15.9) 184 (10.6) 123 (11.6) 102 (9.2) 438 (8.8)  1 518 (6.7) 
Other diagnosis 71 (3.4) 835 (34.1) 0 (0.0) 303 (8.8) 109 (6.9) 586 (26.3) 93 (5.3) 248 (23.3) 26 (2.3) 414 (8.4)  2 685 (11.8) 
No diagnosis 102 (4.9) 185 (7.6) 133 (6.5) 910 (26.5) 199 (12.6) 263 (11.8) 49 (2.8) 69 (6.5) 22 (2.0) 776 (15.7)  2 708 (11.9) 
Antibiotic 
prescribed 
1246 (60.2) 999 (40.8) 1506 (74.5) 2241 (65.2) 1173 (74.6) 879 (39.4) 1046 (60.5) 525 (49.3) 609 (54.8) 3372 (68.0)  13 638 (60.1) 
SD: standard deviation. 
a All values in the table represent absolute numbers and percentages unless otherwise stated. 
b The total number of physician types may not equal the number of consultations observed because nonclinical personnel (such as laboratory officers) conducted the 
consultations in some cases. 
c The technical qualification of health-care assistants was country-specific; assistants included community health workers, medical assistants or officers and clinical 
assistants or officers. 
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Table 5. Antibiotic availability at health facilities, service provision assessment and service availability and readiness 
assessment surveys in low- and middle-income countries, 2004–2017 
Type of 
antibiotica 
No. of health facilities with antibiotic available / no. of facilities providing information (%) Availability 
median % 
(IQR) 
Country or territory and year of surveyb 
Banglades
h 2014 
Benin 
2014 
Democratic 
Republic of 
the Congo 
2013 
Egypt 
2004 
Guyana 
2004 
Haiti 2013 Kenya 
2010 
Malawi 
2013–
2014 
Mauritani
a 2013 
Namibia 
2009 
Nepal 
2015 
Rwanda 
2017 
Senegal 
2017 
Sierra 
Leone 
2016 
Somalia 
2012 
Togo 
2013 
Uganda 
2005 
United 
Republic of 
Tanzania 
2014–2015 
Zambia 
2015 
Zanzibar
2012 
Zimbab
we 
2015 
 
Access (oral)                       
Amoxicillin 1410/1506 
(93.6) 
731/770 
(94.5) 
1010/1254 
(80.5) 
345/464 
(74.4) 
82/110 
(74.5) 
781/887 
(88.0) 
389/640 
(60.8) 
857/964 
(88.9) 
153/164 
(93.3) 
326/389 
(83.8) 
846/918 
(92.2) 
405/486 
(83.3) 
325/367 
(88.6) 
34/449 
(7.6) 
35/56 
(62.5) 
3/99 
(3.0) 
200/479 
(41.8) 
1028/1170 
(87.9) 
348/401 
(86.8) 
31/75 
(41.3) 
1410/15
06 
(93.6) 
83.8 (26.4) 
Amoxicillin with 
clavulanate 
295/1506 
(19.6) ND ND ND ND 
154/887 
(17.4) 
220/640 
(34.4) 
125/964 
(13.0) ND 
31/389 
(8.0) 
224/918 
(24.4) 
95/486 
(19.5) 
73/367 
(19.9) ND ND ND 
39/479 
(8.1) 
178/1170 
(15.2) 
53/399 
(13.3) ND 
295/150
6 (19.6) 
17.4 (6.9) 
Ampicillin 263/1506 
(17.5) 
541/773 
(70.0) 
1025/1314 
(78.0) 
178/461 
(38.6) 
37/110 
(33.6) 
257/887 
(29.0) 
123/640 
(19.2) 
70/964 
(7.3) 
130/159 
(81.8) 
66/389 
(17.0) 
137/918 
(14.9) 
345/486 
(71.0) 
304/367 
(82.8) 
302/447 
(67.6) 
47/71 
(66.2) 
23/99 
(23.2) 
147/479 
(30.7) 
361/1170 
(30.9) 
146/402 
(36.3) 7/75 (9.3) 
263/150
6 (17.5) 
30.9 (50.1) 
Cefalexin 127/1506 
(8.4) ND ND ND ND ND 
112/640 
(17.5) ND ND 
10/389 
(2.6) ND 
5/486 
(1.0) ND ND ND ND 
32/479 
(6.7) ND 
80/401 
(20.0) ND 
127/150
6 (8.4) 
7.6 (14.9) 
Chloramphenicol ND ND ND ND ND ND 147/640 (23.0) ND ND 
45/389 
(11.6) 
374/918 
(40.7) 
247/486 
(50.8) ND ND ND ND 
158/479 
(33.0) ND 
186/401 
(46.4) ND ND 
36.9 (23.4) 
Clindamycin ND ND ND ND ND ND 60/640 (9.4) ND ND 
32/389 
(8.2) ND 
5/486 
(1.0) ND ND ND ND 
10/479 
(2.1) ND 
6/401 
(1.5) ND ND 
2.1 (6.7) 
Cloxacillin 268/1506 
(17.8) 
770/770 
(100.0) ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
109/402 
(27.1) ND 
268/150
6 (17.8) 
27.1 (82.2) 
Co-trimoxazole 1313/1506 
(87.2) 
764/770 
(99.2) 
1103/1254 
(88.0) 
304/463 
(65.7) ND 
730/887 
(82.3) 
580/640 
(90.6) 
906/964 
(94.0) 
148/163 
(90.8) 
372/389 
(95.6) 
815/918 
(8.8) 
438/486 
(90.1) 
249/367 
(67.8) 
274/449 
(61.0) 
48/56 
(85.7) 
99/99 
(100.0) 
380/479 
(79.3) 
1057/1170 
(90.3) 
301/402 
(74.9) 
68/75 
(90.7) 
1313/15
06 
(87.2) 
89.5 (11.6) 
Doxycycline 1113/1506 
(73.9) ND ND 
19/462 
(4.1) 
61/110 
(55.5) 
574/887 
(64.7) 
488/640 
(76.2) 
838/964 
(86.9) ND 
333/389 
(85.6) 
408/918 
(44.4) 
389/486 
(80.0) 
299/367 
(81.5) ND ND ND 
351 /479 
(73.3) 
893/1170 
(76.3) 
358/402 
(89.1) ND 
1113/15
06 
(73.9) 
76.3 (16.8) 
Metronidazole 1422/1506 
(94.4) 
730/770 
(94.8) 
1044/1254 
(83.3) ND 
80/110 
(72.7) 
641/887 
(72.3) 
425/640 
(66.4) 
862/964 
(89.4) 
145/161 
(90.1) 
349/389 
(89.7) 
882/918 
(96.1) 
424/486 
(87.2) 
297/367 
(80.9) ND 
46/56 
(82.1) 
86/99 
(86.9) 
355/479 
(74.1) 
847/1170 
(72.4) 
361/402 
(89.8) ND 
1422/15
06 
(94.4) 
87.1 (15.9) 
Penicillin 710/1506 
(47.1) ND ND 
30/463 
(6.5) ND ND 
55/640 
(8.6) 
133/964 
(13.8) ND 
324/389 
(83.3) ND 
349/486 
(71.8) ND ND ND ND 
105/479 
(21.9) ND 
253/400 
(63.2) ND 
710/150
6 (47.1) 
34.5 (56.3) 
Tetracycline 502/1506 
(33.3) ND ND 
295/464 
(63.6) ND 
156/887 
(17.6) 
84/640 
(13.1) 
66/964 
(6.8) ND 
6/389 
(1.5) 
403/918 
(43.9) 
111/486 
(22.8) 
11/367 
(3.0) ND ND ND 
45/479 
(9.4) 
77/1170 
(6.6) 
72/402 
(17.9) ND 
502/150
6 (33.3) 
15.4 (21.4) 
Access 
(intravenous)                      
 
Benzathine 
benzylpenicillin 
136/1506 
(9.0) 
685/716 
(95.7) 
734/1314 
(55.9) 
322/463 
(69.5) 
37/110 
(33.6) 
266/887 
(30.0) 
482/640 
(75.3) 
836/964 
(86.7) 
85/157 
(54.1) 
276/389 
(71.0) ND 
416/486 
(85.6) 
273/367 
(74.4) 
18/447 
(4.0) 
43/71 
(60.6) 
5/99 
(5.1) 
267/479 
(55.7) 
857/1170 
(73.2) ND 
46/75 
(61.3) 
136/150
6 (9.0) 
61.3 (41.7) 
Chloramphenicol ND 69/770 (9.0) ND ND ND ND 
276/640 
(43.1) ND ND 
36/389 
(9.3) ND 
234/486 
(48.1) ND ND ND ND 
256/479 
(53.4) ND 
128/402 
(31.8) ND ND 
37.5 (38.9) 
Gentamycin 195/1506 
(12.9) 
660/773 
(85.4) 
300/1314 
(22.8) 
219/464 
(47.2) 
40/110 
(36.4) 
254/887 
(28.6) 
503/640 
(78.6) 
829/964 
(86.0) 
121/159 
(76.1) 
119/389 
(30.6) 
669/918 
(72.9) 
266/496 
(54.7) 
301/367 
(82.0) 
446/451 
(98.9) 
47/71 
(66.2) 
84/99 
(84.8) 
233/479 
(48.6) 
591/1170 
(50.5) 
242/401 
(60.3) 
10/75 
(13.3) 
195/150
6 (12.9) 
56.6 (42.2) 
Metronidazole 225/1506 
(14.9) ND ND 
308/464 
(66.4) ND 
148/887 
(16.7) ND 
106/964 
(11.0) ND ND 
328/918 
(35.7) ND 
239/367 
(65.1) ND ND ND ND 
443/1170 
(37.9) ND ND 
225/150
6 (14.9) 
35.7 (50.2) 
Penicillin 93/1506 
(6.2) ND ND ND ND 
247/887 
(27.8) ND 
478/964 
(49.6) ND ND 
71/918 
(7.7) ND 
67/367 
(18.3) ND ND ND ND 
738/1170 
(63.1) ND ND 
93/1506 
(6.2) 
23.1 (41.9) 
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Procaine 
benzylpenicillin ND 
565/770 
(73.4) 
641/1254 
(51.1) 
244/464 
(52.6) 
47/110 
(42.7) ND 
180/640 
(28.1) ND 
52/163 
(31.9) 
97/389 
(24.9) ND 
403/486 
(82.9) ND 
84/447 
(18.8) ND 
84/99 
(84.8) 
347/479 
(72.4) ND 
381/402 
(94.8) 
70/75 
(93.3) ND 
52.6 (51.0) 
Streptomycin 114/217 
(52.5) 
110/322 
(34.2) 
374/578 
(64.7) 
94/464 
(20.3) ND 
107/269 
(39.8) ND 
68/384 
(17.7) 
24/48 
(50.0) ND ND ND 
47/367 
(31.1) 
433/446 
(97.1) 
11/13 
(84.6) 
29/36 
(80.6) ND 
232/569 
(40.8) 
211/402 
(52.5) ND 
114/217 
(52.5) 
51.2 (46.4) 
Watch (oral)                       
Azithromycin 406/1506 
(27.0) 
685/773 
(88.6) 
374/1314 
(28.5) ND ND 
229/887 
(25.8) ND 
375 
/964 
(38.9) 
19/158 
(12.0) ND 
311/918 
(33.9) ND 
14/367 
(4.8) 
325/447 
(72.7) 
30/71 
(42.3) 
6/99 
(6.1) ND 
335/1170 
(28.6) ND 
10/75 
(13.3) 
406/150
6 (27.0) 
27.7 (8.1) 
Cefixime 309/1506 
(20.5) 
430/773 
(55.6) 
505/1314 
(38.4) ND ND 
72/887 
(8.1) ND 
40/964 
(4.1) 
20/159 
(12.6) ND 
233/918 
(25.4) ND 
77/367 
(21.0) 
28/447 
(6.3) 
18/71 
(25.4) ND ND 
100/1170 
(8.5) ND 1/75 (1.3) 
309/150
6 (20.5) 
14.5 (12.9) 
Ciprofloxacin 883/1506 
(58.6) 
701/770 
(91.0) 
833/1254 
(66.4) 
18/461 
(3.9) 
48/110 
(43.6) 
545/887 
(61.4) 
413/640 
(64.5) 
528/964 
(54.8) 
65/162 
(40.1) 
340/389 
(87.4) 
301/918 
(32.8) 
360/486 
(74.1) 
324/367 
(88.3) 
146/449 
(32.5) 
27/56 
(48.2) 
77/99 
(77.8) 
311/479 
(64.9) 
936/1170 
(80.0) 
212/402 
(52.7) 9/75 (12) 
883/150
6 (58.6) 
58.6 (34.0) 
Clarithromycin ND ND ND ND ND ND 80/640 (12.5) ND ND 
16/389 
(4.1) ND 
8/486 
(1.6) ND ND ND ND 
10/479 
(2.1) ND 
17/402 
(4.2) ND ND 
4.1 (2.1) 
Erythromycin 260/1506 
(17.3) 
416/596 
(69.8) ND 
97/464 
(20.9) 
71/110 
(64.5) 
578/887 
(65.2) 
407/640 
(63.6) 
840/964 
(87.1) ND 
323/389 
(83.0) 
113/918 
(12.3) 
399/486 
(82.1) 
208/367 
(56.7) ND ND ND 
229/479 
(47.8) 
916/1170 
(78.3) 
333/402 
(82.8) ND 
260/150
6 (17.3) 
64.9 (34.3) 
Watch 
(intravenous)                      
 
Cefotaxime ND ND ND ND ND ND 41/640 (6.4) ND ND 
13/389 
(3.3) ND 
37/486 
(7.6) ND ND ND ND 
4/479 
(0.8) ND 
56/399 
(14.0) ND ND 
6.4 (4.3) 
Ceftriaxone 288/1506 
(19.1) 
418/770 
(54.3) 
578/1274 
(46.1) 
20/462 
(4.3) ND 
265/887 
(29.9) 
281/640 
(43.9) 
484/964 
(50.2) 
29/162 
(17.9) 
309/389 
(79.4) 
214/918 
(23.3) 
33/486 
(6.8) 
248/367 
(67.6) 
397/449 
(88.4) 
32/56 
(57.1) 
43/99 
(43.4) 
95/479 
(19.8) 
765/1170 
(65.4) 
42/402 
(10.4) 19/75 (25) 
288/150
6 (19.1) 
43.7 (36.2) 
Unclassified                      
 
Kanamycin 
(intravenous) ND ND ND ND ND ND 
24/640 
(3.8) ND ND 
24/389 
(6.2) ND 
4/486 
(0.8) ND ND ND ND 
0/479 
(0.0) ND 
99/402 
(24.6) ND ND 
4 (5.3) 
IQR: interquartile range; ND: not determined. 
a Antibiotics were classified using the World Health Organization’s AWaRe categories. See Box 1. 
b A service provision assessment survey or service availability and readiness assessment survey was carried out in each country or territory (Table 3). 
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Table 6. Proportion of children prescribed an antibiotic during consultations, by diagnosis, service provision assessment 
surveys, 2004–2017 
Diagnosis No. (%) of children prescribed an antibiotica 
Country (year) of survey Total 
Egypt 
(2004) 
Haiti 
(2013) 
Kenya 
(2010) 
Malawi 
(2013–14) 
Namibia 
(2009) 
Nepal 
(2015) 
Rwanda 
(2017) 
Senegal 
(2017) 
Uganda 
(2005) 
United 
Republic of 
Tanzania 
(2014–2015) 
Pneumonia 87 (84.5) 40 (66.7) 300 (96.2) 394 (97.5) 134 (92.4) 109 (61.6) 111 (83.5) 75 (68.2) 118 (79.7) 630 (96.0) 1 998 (88.9) 
Ear infection 43 (93.5) 56 (80.0) 49 (92.5) 72 (97.3) 38 (82.6) 53 (49.1) 37 (74.0) 10 (83.3) 19 (65.5) 50 (78.1) 427 (77.4) 
Throat infection 467 (84.9) 18 (72.0) 29 (87.9) 16 (88.9) 51 (92.7) 3 (12.0) 56 (67.5) 5 (50.0) 2 (50.0) 75 (84.3) 722 (80.9) 
Asthma 0 (0.0) 26 (56.5) 32 (76.2) 17 (73.9) 8 (72.7) 0 (0.0) 3 (50.0) 6 (35.3) 12 (50.0) 20 (62.5) 124 (59.0) 
Other respiratory tract infection 403 (62.1) 253 (41.8) 814 (84.9) 1092 (89.4) 624 (81.1) 146 (32.0) 614 (69.1) 179 (54.1) 345 (65.7) 1231 (82.6) 5 701 (72.2) 
Malaria 0 (0.0) 40 (37.7) 98 (32.9) 43 (23.4) 8 (44.4) 0 (0.0) 15 (38.5) 2 (16.7) 33 (24.4) 113 (31.1) 352 (30.3) 
Diarrhoea 179 (36.6) 154 (39.8) 111 (65.3) 99 (37.8) 117 (63.2) 60 (24.5) 103 (44.6) 34 (25.8) 37 (38.1) 399 (62.9) 1 293 (45.7) 
Undifferentiated fever 32 (54.2) 53 (40.5) 16 (34.0) 26 (68.4) 23 (56.1) 116 (32.7) 69 (37.5) 77 (62.6) 30 (29.7) 318 (72.6) 760 (50.1) 
Other diagnosis 17 (23.9) 323 (38.7) 0 (0.0) 124 (40.9) 47 (43.1) 288 (49.1) 35 (37.6) 108 (43.5) 11 (42.3) 207 (50.0) 1 160 (43.2) 
No diagnosis given 18 (17.6) 36 (19.5) 77 (57.9) 358 (39.3) 127 (63.8) 104 (39.5) 21 (42.9) 29 (42.0) 2 (9.1) 329 (42.4) 1 101 (40.7) 
Total 1246 (60.2) 999 (40.8) 1526 (74.5) 2241 (65.2) 1177 (74.6) 879 (39.4) 1064 (60.6) 525 (49.3) 609 (54.8) 3372 (68.0) 13 638 (60.1) 
a Percentages were calculated using the number of children diagnosed with the condition in each country given in Table 4. 
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Fig. 1. Antibiotic availability at health facilities, service provision assessment and 
service availability and readiness assessment surveys in low- and middle-income 
countries, 2004–2017 
 
 
Notes: The bars represent the median availability across all countries surveyed. Antibiotics were classified 
using the World Health Organization’s AWaRe categories (Box 1). 
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Fig. 2. Proportion of children prescribed antibiotics, by antibiotic type and 
diagnosis, service provision assessment surveys in 10 low- and middle-income 
countries, 2004–2017 
 
 
Notes: Percentages represented are the median of prescribed antibiotics across all countries surveyed. 
Diagnoses were made by health-care providers in consultations observed during service provision 
assessment surveys. For Rwanda and Uganda, which recorded amoxicillin and co-trimoxazole in a single 
category, we assigned all entries in that category to co-trimoxazole because the availability of co-
trimoxazole was greater than that of amoxicillin in both countries. Other respiratory tract infection includes 
unspecified upper respiratory infection and other unknown respiratory illnesses. Undifferentiated fever 
includes cases where the cause of the fever was not known or the diagnosis was measles. Diarrhoea 
includes diarrhoea and dysentery. An observation was classified as no diagnosis when no diagnosis was 
recorded but treatment was still given. The data for each country is available from the corresponding 
author. 
 
